Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects
ClinicalTrials.gov · NCT06247748 · Registry updated: 2024-08-21
- Condition / research focus
- Diabetes Mellitus, Type 2; Overweight
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2023-10-19. Completion: 2024-04-15 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Exendin-4 Fc fusion protein (JY09) injection (drug) — also listed as: JY09
- Metformin Hydrochloride tablet (drug) — also listed as: Metformin
- Rosuvastatin calcium tablets (drug) — also listed as: Rosuvastatin
- Digoxin tablet (drug) — also listed as: digoxin
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.